Chair of the Board · Theravance Biopharma, Inc. (TBPH)

Chair, Strategic Review Committee

Susannah Gray director compensation at Theravance (FY2025): $348K

Fiscal year 2025 director compensation for Susannah Gray at Theravance Biopharma, Inc.. Every figure below is printed as the company filed it and cited to the filing it came from.

Director compensation as of the proxy filed April 28, 2026 (DEF 14A). Open the filing on EDGAR.

Free

Get Susannah Gray’s full pay file as a PDF — free

More than this page: up to 10 years of Susannah’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Susannah Gray and every company like it: Velarion Intel, free for 3 days, no card →

What they were paid

Theravance Biopharma Director Compensation Table · all 3 fiscal years held
In US dollars, as Theravance Biopharma reports it. Most recent year first. Totals are the company’s disclosed totals.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$123,356$99,994$124,929$0$348,279
FY2024$76,584$99,996$124,833—$301,413
FY2023$52,600$216,649$293,873—$563,122

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Theravance Biopharma, Inc. DEF 14A filed April 28, 2026, accession 0001104659-26-050454, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Theravance Biopharma, Inc. filed document, accession 0001104659-26-050454. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2026.

Get the Theravance Biopharma Board Governance Report

$348,279 Susannah Gray, FY2025 total director compensation

$500

The free page is the headline figures. The board report is director pay, board composition and committee fees combined into the same kind of document.

Data as of April 28, 2026 · Source: Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

Committees

FY2025 · as the proxy prints them

Audit · Strategic Review Committee (Chair)

The rest of the Theravance Biopharma board

FY2025 · as the company reported each
DirectorRoleFY2025 total
Dean J. MitchellIndependent Director$304,923
Deepika R. Pakianathan, Ph.DIndependent Director$317,423
Donal O'ConnorDirector$319,923
Eran BroshyIndependent Director$305,923
James KellyIndependent Director$55,000
Jeremy T. GrantIndependent Director$297,423
Laurie Smaldone Alsup, M.DIndependent Director$291,423
Rick E WinninghamDirector—

The full Theravance Biopharma compensation record

free company brief

This page is one director within Theravance Biopharma's record. The company brief lists every named executive and director, each linking to their own page.

Order TBPH

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Board Governance Report